Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm has commenced an investigation into ProNAi Therapeutics, Inc. (DNAI) (“ProNAi”) relating to potential violations of federal securities laws.
ProNAi is a clinical stage oncology company with a focus on pioneering a novel class of therapeutics based on its proprietary DNA interference (“DNAi”) technology platform. ProNAi’s lead product candidate is PNT2258, a proprietary formulation of PNT100, a single-stranded 24-base DNAi oligonucleotide, for the treatment of relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”); and Richter’s transformed chronic lymphocytic leukemia.
On June 6, 2016, ProNAi announced interim results from the Wolverine Phase 2 trial and revealed that, “[a]lthough [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine,” the Company has “decided to suspend the development of PNT2258” because the results were not “robust enough to justify continued development of the drug in DLBCL.”
On this news, the price of the Company’s stock dropped over 67%, from $6.38 per share to $2.07 per share.
What You Can Do
If you are a ProNAi shareholder you may have legal claims against ProNAi. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Amber L. Eck at (619) 342-8000 or via email at email@example.com.